[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:systemic-lupus-erythematosus":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":311,"states":340},"Systemic Lupus Erythematosus",106,85,[8,16,23,29,35,42,48,54,60,66,73,79,85,91,97,103,109,115,121,127,132,138,144,150,156,162,168,174,179,185,191,197,203,209,215,222,228,234,240,246,252,258,264,269,275,281,287,293,299,305],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06570798","A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases",[12],"Phase 2","RECRUITING","2026-08-26T02:15:10.362237Z","2026-07-24T01:27:14.890537Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07438496","A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus",[20],"Phase 3","2026-08-26T02:18:48.678868Z","2026-07-19T19:36:05.072746Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT05835310","An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants",[20],"2026-08-26T02:17:26.640202Z","2026-07-05T05:32:16.816417Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT05440422","The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD",[12],"2026-08-26T02:16:41.943926Z","2026-07-05T05:32:16.802874Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":40,"content_modified":41},"NCT06594068","Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users",[39],"Phase 4","2026-08-26T02:16:16.169331Z","2026-07-05T05:32:16.760272Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06411249","A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)",[39],"2026-08-26T02:18:38.865010Z","2026-07-05T05:32:16.755824Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT07053800","Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)",[12],"2026-08-26T02:15:42.447052Z","2026-07-05T05:32:16.729991Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT07015983","A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)",[12],"2026-08-03T00:59:52.468532Z","2026-07-05T05:32:16.725542Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT07225543","2-HOBA in Systemic Lupus Erythematosus",[12],"2026-08-26T02:17:15.156099Z","2026-07-05T05:32:16.667271Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":71,"content_modified":72},"NCT07201558","Study Evaluating Safety, Tolerability, PK\u002FPD of Surovatamig in Adult RA or SLE Participants",[70],"Phase 1","2026-08-26T02:17:36.611194Z","2026-07-05T05:32:16.666464Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT05268289","Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +\u002F- V",[12],"2026-08-26T02:18:22.309547Z","2026-05-29T15:36:40.174644Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT07430306","A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus",[20],"2026-08-26T02:17:06.985283Z","2026-05-13T02:55:06.705839Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT05029336","Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases",[12],"2026-08-26T02:19:10.436356Z","2026-05-05T02:43:29.737040Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT05799378","Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease",[20],"2026-08-26T02:18:19.586423Z","2026-05-05T02:43:29.732670Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT07355218","A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)",[20],"2026-08-26T02:17:45.190188Z","2026-05-05T02:43:29.726637Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT06465147","REACT-01: Reversing Autoimmunity Through Cell Therapy",[70],"2026-08-26T02:16:04.914942Z","2026-05-05T02:43:29.396976Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":107,"content_modified":114},"NCT06121297","RESET-SLE: A Phase 1\u002F2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus",[113],"Phase 1\u002FPhase 2","2026-05-05T02:43:29.164988Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT06133972","Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).",[20],"2026-08-26T02:15:38.131683Z","2026-05-05T02:43:28.899728Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT06897930","A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE",[113],"2026-08-26T02:16:35.654046Z","2026-05-05T02:43:28.793672Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":14,"content_modified":131},"NCT06581198","A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE\u002FLN)",[12],"2026-05-05T02:43:28.728724Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":136,"content_modified":137},"NCT07219563","Alnuctamab for Refractory SLE (LATTE Study)",[70],"2026-08-26T02:19:31.671303Z","2026-05-05T02:43:28.475692Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT03543839","Trial of Belimumab in Early Lupus",[39],"2026-08-26T02:15:24.145250Z","2026-05-05T02:43:28.299250Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT06032923","Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus",[113],"2026-08-26T02:16:00.194860Z","2026-05-05T02:43:28.186327Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT06975787","Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis",[70],"2026-08-26T02:18:31.944757Z","2026-05-05T02:43:27.859952Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":160,"content_modified":161},"NCT06625671","A Phase 1\u002F2a Study of DB-2304 in Healthy Adults and SLE Participants",[113],"2026-08-26T02:18:30.351130Z","2026-05-05T02:43:27.671925Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":166,"content_modified":167},"NCT06737380","UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients",[70],"2026-08-26T02:15:03.757872Z","2026-05-05T02:43:27.646843Z",{"nct_id":169,"title":170,"phases":171,"status":13,"updated_at":172,"content_modified":173},"NCT07011043","A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)",[70],"2026-08-26T02:15:34.659160Z","2026-05-05T02:43:27.577016Z",{"nct_id":175,"title":176,"phases":177,"status":13,"updated_at":21,"content_modified":178},"NCT05559671","Safety of the Herpes Zoster Subunit Vaccine in Lupus",[39],"2026-05-05T02:43:27.476510Z",{"nct_id":180,"title":181,"phases":182,"status":13,"updated_at":183,"content_modified":184},"NCT06613360","A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus",[70],"2026-08-26T02:18:03.638950Z","2026-05-05T02:43:27.314554Z",{"nct_id":186,"title":187,"phases":188,"status":13,"updated_at":189,"content_modified":190},"NCT06559163","A Study of Obexelimab in Patients With Systemic Lupus Erythematosus",[12],"2026-08-03T02:04:08.415522Z","2026-05-05T02:43:27.254241Z",{"nct_id":192,"title":193,"phases":194,"status":13,"updated_at":195,"content_modified":196},"NCT07260877","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus",[12],"2026-08-26T02:18:05.435729Z","2026-05-05T02:43:27.251049Z",{"nct_id":198,"title":199,"phases":200,"status":13,"updated_at":201,"content_modified":202},"NCT06977724","A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)",[70],"2026-08-26T02:17:57.117858Z","2026-05-05T02:43:26.921745Z",{"nct_id":204,"title":205,"phases":206,"status":13,"updated_at":207,"content_modified":208},"NCT06232304","Transforming Care for Individuals With Childhood-onset Systemic Lupus Erythematosus",[],"2026-08-26T02:15:20.225313Z","2026-05-05T02:43:26.757659Z",{"nct_id":210,"title":211,"phases":212,"status":13,"updated_at":213,"content_modified":214},"NCT06617325","A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus",[20],"2026-08-26T02:16:42.787115Z","2026-05-05T02:35:31.934489Z",{"nct_id":216,"title":217,"phases":218,"status":13,"updated_at":220,"content_modified":221},"NCT07107659","Safety and Efficacy of ONT01 in Lupus",[219],"Early Phase 1","2026-08-26T02:18:06.247899Z","2026-05-05T02:35:31.927773Z",{"nct_id":223,"title":224,"phases":225,"status":13,"updated_at":226,"content_modified":227},"NCT07409181","A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)",[12],"2026-08-26T02:18:49.989941Z","2026-05-05T02:35:31.877860Z",{"nct_id":229,"title":230,"phases":231,"status":13,"updated_at":232,"content_modified":233},"NCT06839976","CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus",[113],"2026-08-26T02:17:20.511551Z","2026-05-05T02:35:31.669019Z",{"nct_id":235,"title":236,"phases":237,"status":13,"updated_at":238,"content_modified":239},"NCT06340750","BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus",[70],"2026-08-26T02:17:43.321968Z","2026-04-29T02:57:57.115339Z",{"nct_id":241,"title":242,"phases":243,"status":13,"updated_at":244,"content_modified":245},"NCT07085104","A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease",[70],"2026-08-26T02:16:26.411851Z","2026-07-30T01:46:14.415751Z",{"nct_id":247,"title":248,"phases":249,"status":13,"updated_at":250,"content_modified":251},"NCT06576271","A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants",[70],"2026-08-26T02:18:13.438956Z","2026-07-05T05:32:16.765412Z",{"nct_id":253,"title":254,"phases":255,"status":13,"updated_at":256,"content_modified":257},"NCT05869955","A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)",[70],"2026-08-03T03:31:16.569358Z","2026-05-05T02:43:29.019382Z",{"nct_id":259,"title":260,"phases":261,"status":13,"updated_at":262,"content_modified":263},"NCT06916806","A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.",[70],"2026-08-26T02:18:01.700186Z","2026-05-05T02:43:28.362747Z",{"nct_id":265,"title":266,"phases":267,"status":13,"updated_at":195,"content_modified":268},"NCT07115745","A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases",[70],"2026-05-05T02:43:27.679553Z",{"nct_id":270,"title":271,"phases":272,"status":13,"updated_at":273,"content_modified":274},"NCT06208514","Brief Pain Exposure Therapy (BPET) For Nociplastic Pain",[],"2026-08-26T02:15:00.557154Z","2026-05-05T02:43:27.416794Z",{"nct_id":276,"title":277,"phases":278,"status":13,"updated_at":279,"content_modified":280},"NCT06925542","A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease",[70],"2026-08-26T02:17:18.747857Z","2026-05-05T02:43:27.245332Z",{"nct_id":282,"title":283,"phases":284,"status":13,"updated_at":285,"content_modified":286},"NCT07089121","Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders",[113],"2026-08-26T02:16:38.897933Z","2026-05-05T02:43:27.171088Z",{"nct_id":288,"title":289,"phases":290,"status":13,"updated_at":291,"content_modified":292},"NCT06875960","A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and\u002For Subacute Cutaneous Lupus Erythematosus (DLE\u002FSCLE) Who Have Completed Study IM011074 or Study IM011132",[39],"2026-08-26T02:15:29.632183Z","2026-05-05T02:43:26.850740Z",{"nct_id":294,"title":295,"phases":296,"status":13,"updated_at":297,"content_modified":298},"NCT06434363","Phase I\u002FII Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders",[113],"2026-08-26T02:18:52.966503Z","2026-05-05T02:43:26.675534Z",{"nct_id":300,"title":301,"phases":302,"status":13,"updated_at":303,"content_modified":304},"NCT06308978","A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease",[70],"2026-08-26T02:15:13.282904Z","2026-04-29T02:57:57.084867Z",{"nct_id":306,"title":307,"phases":308,"status":13,"updated_at":309,"content_modified":310},"NCT05508009","Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor",[113],"2026-08-26T02:15:47.754948Z","2026-05-05T02:43:28.845160Z",[312,316,319,323,326,330,334,337],{"biomarker":313,"count":314,"slug":315},"Anti-ds DNA Antibody",21,"anti-ds-dna-antibody",{"biomarker":317,"count":314,"slug":318},"Antinuclear Antibody","antinuclear-antibody",{"biomarker":320,"count":321,"slug":322},"anti-Sm",5,"anti-sm",{"biomarker":324,"count":321,"slug":325},"anti-Smith","anti-smith",{"biomarker":327,"count":328,"slug":329},"PRTN3 wt Allele",4,"prtn3-wt-allele",{"biomarker":331,"count":332,"slug":333},"CD19 Gene",3,"cd19-gene",{"biomarker":335,"count":332,"slug":336},"dsDNA","dsdna",{"biomarker":338,"count":332,"slug":339},"RF","rf",[341,345,348,351,355,359,363,366,369,373,377,380,384,387,391,394,398,402,406,410,414,417,420,424],{"state":342,"count":343,"slug":344},"California",41,"california",{"state":346,"count":343,"slug":347},"New York","new-york",{"state":349,"count":343,"slug":350},"Texas","texas",{"state":352,"count":353,"slug":354},"Florida",35,"florida",{"state":356,"count":357,"slug":358},"North Carolina",32,"north-carolina",{"state":360,"count":361,"slug":362},"Illinois",24,"illinois",{"state":364,"count":314,"slug":365},"Michigan","michigan",{"state":367,"count":314,"slug":368},"Pennsylvania","pennsylvania",{"state":370,"count":371,"slug":372},"Ohio",20,"ohio",{"state":374,"count":375,"slug":376},"Georgia",19,"georgia",{"state":378,"count":375,"slug":379},"Maryland","maryland",{"state":381,"count":382,"slug":383},"Arizona",18,"arizona",{"state":385,"count":382,"slug":386},"Louisiana","louisiana",{"state":388,"count":389,"slug":390},"Massachusetts",17,"massachusetts",{"state":392,"count":389,"slug":393},"Tennessee","tennessee",{"state":395,"count":396,"slug":397},"Alabama",16,"alabama",{"state":399,"count":400,"slug":401},"Missouri",15,"missouri",{"state":403,"count":404,"slug":405},"Colorado",14,"colorado",{"state":407,"count":408,"slug":409},"Oklahoma",11,"oklahoma",{"state":411,"count":412,"slug":413},"Minnesota",9,"minnesota",{"state":415,"count":412,"slug":416},"New Jersey","new-jersey",{"state":418,"count":412,"slug":419},"Washington","washington",{"state":421,"count":422,"slug":423},"Iowa",8,"iowa",{"state":425,"count":422,"slug":426},"Utah","utah"]